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Dear Editor,
We  read  with  great  interest  the  article  entitled 
“Noninvasive  assessment  of  liver  fibrosis  with  the 
aspartate transaminase to platelet ratio (APRI): Usefulness 
in patients with chronic liver disease” by Yilmaz Y et al. 
published in a recent issue of Hepatitis Monthly (1). In 
this study, the authors investigated the diagnostic power 
of APRI for predicting hepatic fibrosis in patients with 
chronic hepatitis B (CHB) and C (CHC) and non-alcoholic 
fatty liver disease (NAFLD). The study was retrospectively 
conducted  on  adults  with  chronic  liver  disease  (CHB, 
CHC, or NAFLD) at the Department of Gastroenterology 
of  Marmara  University  (Istanbul).  Yilmaz  et  al. 
demonstrated  that  APRI  was  significantly  associated 
with fibrosis scores in patients with CHC and NAFLD, but 
not in those with CHB. Interestingly, the analysis of the 
ROC curves highlighted that APRI was able to provide an 
acceptable prediction of the presence of liver fibrosis in 
patients with CHC (0.582, P < 0.01) and NAFLD (0.627, P < 
0.01), but not in those with CHB (0.541, P = NS). Therefore, 
the authors concluded that APRI might be a useful test 
for  the  detection  of  liver  fibrosis  which  develops  in 
specific etiologies, including NAFLD and hepatitis virus 
C infection (1). APRI is one of the many indirect, non-
invasive markers of hepatic fibrosis developed in recent 
years to avoid the use of liver biopsy, which, although still 
considered the gold standard for evaluation of fibrosis, 
is  limited  by  its  invasiveness,  risk  of  complications, 
sampling  errors,  and  variability  in  pathological 
interpretation.  APRI  is  composed  of  panels  that    are   
routinely  performed  in patients with liver disease, and 
therefore,  could  be  a  practical  and  convenient  way  to 
follow patients. However, as demonstrated by Yilmaz et 
al., indirect markers such as APRI should be used with 
caution because their sensitivity in predicting fibrosis 
can be strongly influenced by the etiology of fibrosis. A 
relevant limitation of this study is that it was conducted 
in a tertiary liver centre, where the higher proportion 
of  patients  with  advanced  diseases  might  represent  a 
selection bias with respect to a population observed in 
a more general setting. An additional limitation of APRI 
is represented by its inability to identify mild forms of 
liver fibrosis. In fact, aspartate transaminase (AST) serum 
levels  and  platelet  counts  become  altered  mainly  in 
advanced stages of hepatic disease; thus, APRI could be 
ineffective in detecting early liver fibrosis.Hepat Mon. 2011;11(7):558-559
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Furthermore, we would like to highlight the fact that 
at least one other factor has to be carefully considered 
in the use of indirect markers such as APRI: the age of 
patients. In fact, some pediatric studies demonstrated 
that  APRI  was  diagnostically  useful  only  in  a  specific 
pediatric setting (2-4). Moreover, although Yilmaz et al. 
had shown that APRI is a useful marker for liver fibrosis 
in  adult  patients  with  NAFLD,  this  is  not  the  case  in 
pediatric  patients  with  the  same  disease.  In  fact,  as 
shown in Figure 1, we found no statistically significant 
difference between the APRI value from NAFLD children 
without fibrosis (F = 0) and those with fibrosis (F ≥ 1). This 
analysis was retrospectively conducted on 100 children 
with biopsy-proven NAFLD observed at our tertiary centre 
of  Liver  Unit  of  the  Bambino  Gesu  Children  Hospital. 
Interestingly,  a  recent  study  conducted  on  the  same 
patients demonstrated that serum levels of hyaluronic 
acid (HA) are good predictors of the degree of hepatic 
fibrosis, independent of others biochemical indices of 
liver damage (5).
In our opinion, this finding makes APRI not suitable 
as a screening program and not adequate to substitute 
liver biopsy, but it could be used to correctly identify 
patients who should be evaluated by biopsy because of 
the high probability of detecting advanced liver damage. 
Noteworthy, the ideal non-invasive method of assessment 
of liver fibrosis would be available at any level of health 
care, from general practice to tertiary care and would 
have the same diagnostic power both in adults and in 
children, independent of the severity of the disease. 
In  conclusion,  although  we  believe  that  greater 
emphasis and importance should be given to the research 
on novel non-invasive fibrosis markers, more studies are 
needed to identify an optimal prediction system useful 
both in adults and in children.
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35 patients with F = 0 and 65 patients with F ≥ 1.
Figure 1. Histogram represents the median value of APRI ± SD in 100 children 
with biopsy-proven NAFLD separated on the basis of presence of fibrosis: 